These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27146313)

  • 1. A comprehensive approach to assess the costs of renal replacement therapy for end-stage renal disease in France: the importance of age, diabetes status, and clinical events.
    Couillerot-Peyrondet AL; Sambuc C; Sainsaulieu Y; Couchoud C; Bongiovanni-Delarozière I
    Eur J Health Econ; 2017 May; 18(4):459-469. PubMed ID: 27146313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [REIN Report 2011--summary].
    Couchoud C; Lassalle M; Jacquelinet C
    Nephrol Ther; 2013 Sep; 9 Suppl 1():S3-6. PubMed ID: 24119584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic impact of a modification of the treatment trajectories of patients with end-stage renal disease.
    Couchoud C; Couillerot AL; Dantony E; Elsensohn MH; Labeeuw M; Villar E; Ecochard R; Bongiovanni I
    Nephrol Dial Transplant; 2015 Dec; 30(12):2054-68. PubMed ID: 26268714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct medical costs of end-stage kidney disease and renal replacement therapy: a cohort study in Guangzhou City, southern China.
    Zhang H; Zhang C; Zhu S; Ye H; Zhang D
    BMC Health Serv Res; 2020 Feb; 20(1):122. PubMed ID: 32059726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost-effectiveness analysis of various strategies of end-stage renal disease patients' care in France].
    Bongiovanni I; Couillerot-Peyrondet AL; Sambuc C; Dantony E; Elsensohn MH; Sainsaulieu Y; Ecochard R; Couchoud C
    Nephrol Ther; 2016 Apr; 12(2):104-15. PubMed ID: 26915892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Projecting prevalence, costs and evaluating simulated interventions for diabetic end stage renal disease in a Canadian population of aboriginal and non-aboriginal people: an agent based approach.
    Gao A; Osgood ND; Jiang Y; Dyck RF
    BMC Nephrol; 2017 Sep; 18(1):283. PubMed ID: 28870154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of end-stage renal disease care in South Asia.
    Jha V
    Ethn Dis; 2009; 19(1 Suppl 1):S1-27-32. PubMed ID: 19484871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The essential of 2012 results from the French Renal Epidemiology and Information Network (REIN) ESRD registry.
    Lassalle M; Ayav C; Frimat L; Jacquelinet C; Couchoud C;
    Nephrol Ther; 2015 Apr; 11(2):78-87. PubMed ID: 25457107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare costs of patients on different renal replacement modalities - Analysis of Dutch health insurance claims data.
    Mohnen SM; van Oosten MJM; Los J; Leegte MJH; Jager KJ; Hemmelder MH; Logtenberg SJJ; Stel VS; Hakkaart-van Roijen L; de Wit GA
    PLoS One; 2019; 14(8):e0220800. PubMed ID: 31415578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. End-stage renal disease-associated managed care costs among patients with and without diabetes.
    Joyce AT; Iacoviello JM; Nag S; Sajjan S; Jilinskaia E; Throop D; Pedan A; Ollendorf DA; Alexander CM
    Diabetes Care; 2004 Dec; 27(12):2829-35. PubMed ID: 15562193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The growing burden of end-stage renal disease in Egypt.
    Soliman AR; Fathy A; Roshd D
    Ren Fail; 2012; 34(4):425-8. PubMed ID: 22260432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding cost of care for patients on renal replacement therapy: looking beyond fixed tariffs.
    Li B; Cairns JA; Fotheringham J; Tomson CR; Forsythe JL; Watson C; Metcalfe W; Fogarty DG; Draper H; Oniscu GC; Dudley C; Johnson RJ; Roderick P; Leydon G; Bradley JA; Ravanan R
    Nephrol Dial Transplant; 2015 Oct; 30(10):1726-34. PubMed ID: 26071229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. End-stage renal disease in Indonesia: treatment development.
    Prodjosudjadi W; Suhardjono A
    Ethn Dis; 2009; 19(1 Suppl 1):S1-33-6. PubMed ID: 19484872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of renal replacement therapy in Austria.
    Haller M; Gutjahr G; Kramar R; Harnoncourt F; Oberbauer R
    Nephrol Dial Transplant; 2011 Sep; 26(9):2988-95. PubMed ID: 21310740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and direct medical costs of end-stage renal disease in patients with type 2 diabetes mellitus in Switzerland for 2001.
    Sandoz MS; Ess SM; Keusch GW; Schwenkglenks M; Szucs TD
    Swiss Med Wkly; 2004 Aug; 134(31-32):448-58. PubMed ID: 15389348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic kidney disease: the distribution of health care dollars.
    St Peter WL; Khan SS; Ebben JP; Pereira BJ; Collins AJ
    Kidney Int; 2004 Jul; 66(1):313-21. PubMed ID: 15200439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. UK Renal Registry 16th annual report: chapter 8 survival and cause of death of UK adult patients on renal replacement therapy in 2012: national and centre-specific analyses.
    Pruthi R; Steenkamp R; Feest T
    Nephron Clin Pract; 2013; 125(1-4):139-69. PubMed ID: 24662172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost consideration in renal replacement therapy in Kenya.
    Were AJ; McLigeyo SO
    East Afr Med J; 1995 Jan; 72(1):69-71. PubMed ID: 7781562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmaco-economic consequences of losartan therapy in patients undergoing diabetic end stage renal disease in EU and USA.
    de Portu S; Citarella A; Cammarota S; Menditto E; Mantovani LG
    Clin Exp Hypertens; 2011; 33(3):174-8. PubMed ID: 21466388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost analysis of the Spanish renal replacement therapy programme.
    Villa G; Rodríguez-Carmona A; Fernández-Ortiz L; Cuervo J; Rebollo P; Otero A; Arrieta J
    Nephrol Dial Transplant; 2011 Nov; 26(11):3709-14. PubMed ID: 21427072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.